Navigation Links
Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference

SAN FRANCISCO, Nov. 4 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biopharmaceutical company, today announced that David H. Kirn, M.D., President and Chief Executive Officer, will present an overview of the Company at the 10th Annual Rodman & Renshaw Healthcare Conference in New York on November 11, 2008 at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) at the Palace Hotel, New York.

A webcast of the presentation will be available during the event at and will be archived and available on the website for 3 months.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
2. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
3. Alexion to Present at Investor Conferences
4. IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference
5. Jazz Pharmaceuticals to Present at Investor Conferences
6. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
7. XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11
8. The Quantum Group Inc. To Present at Paulson Investments 31st Annual Westergaard Conference
9. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
10. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
11. BD to Present at Investor Healthcare Conferences
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
Breaking Medicine Technology: